Dear Colleagues,

On a global scale, the pharmaceutical market is expected to grow in the years to come regardless of a recent slowdown in key markets across the globe. The increase is exacerbated by the growing and ageing population in key markets. Aside from this, increasing access to Pharmaceuticals to poor and middle-class families due to increases in disposable income also drives the industry’s growth. Pharma companies focusing on Rare and speciality medicines is another aspect leading the growth. Innovations attracting investments even from non-pharma companies are also sustaining the growth in the pharmaceutical industry.

The pharmaceutical industry is one of the major players in the healthcare sector. Payers want to provide access and fund innovative treatments to improve patient care but governments across Europe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, national governments and regional authorities.

As healthcare budgets are continuously rising in Europe, governments implement a wide variety of policies to control them with the help of different public regulatory bodies that are involved in pharmaceutical coverage decisions across Europe. International collaboration among HTA and regulatory bodies can promote knowledge exchange, as do the actions payers take in an effort to reduce costs while maintaining quality care.

RWE is playing an increasingly critical role in supporting every aspect of successful evidence-
generation programs and presents immense possibilities, it also brings substantial challenges that continue to cast shadows on its validity. Concerns such as data viases, data quality, and
the possible false results due to data mining, progress have diminished primarily.

The upcoming 2024 RWE, Market Access, Pricing and Reimbursement Global Congress Europe will present a dynamic approach to key trends and insights on market access, health
technology assessment, real-world data, patient access, pricing and reimbursement on the current European landscape.

This year, we are putting together an agenda that addresses “Trends and Strategies to Achieve Optimum Patient Access to Healthcare”. We are gathering together high calibre expert speakers to participate and share their knowledge and expertise through Keynote Presentations and Panel discussions, addressing all aspects of the industry.

We look forward to welcoming you to the RWE, MAPR 2024 congress!

Sincerely yours,